Nano-X Imaging

Nano-X Imaging Ltd. is engaged in the development of medical imaging systems. Its product Nanox System consists of hardware Nanox.ARC and software Nanox.CLOUD that provides image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic assistive artificial intelligence systems, billing, and reporting. The firm operates through the following segments: Nanox.Arc, AI Solutions, and Radiology Services. The company was founded by Ran Poliakine and Hitoshi Masuya in 2011 and is headquartered in Neve Ilan, Israel.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Nano-X Imaging reports progress in regulatory clearances and strategic partnerships

Nano-X Imaging showcased progress in regulatory clearances, commercialization efforts, strategic partnerships, and operational optimization during the Q4 2022 Earnings Call.
Despite challenges in regulatory compliance, expenses management, and market competition, the company's strengths in innovation, partnerships, and financial resilience position it well for future growth.
Opportunities for Nano-X Imaging include global expansion, technological advancements, cost efficiencies, and leveraging market demand for imaging solutions.
Overall, Nano-X Imaging's performance in Q4 2022 reflects a strategic focus on growth, innovation, and market expansion in the medical imaging industry.

Nano-X Imaging reports improved Q1 performance and expands global reach

Nano-X Imaging's Q1 2023 performance showed improvement with a reported net loss of $11.8 million and revenue of $2.4 million. The company is focusing on deploying Nanox.ARC globally, strengthening manufacturing capabilities, and expanding market reach through strategic partnerships. Challenges include managing expenses and driving revenue growth to achieve profitability.

Nanox Imaging reports Q2 results, eyes U.S. market growth

Nanox Imaging's Q2 2023 performance reflects investment in growth initiatives, with a focus on market expansion and product deployment.
The company faces financial challenges, including a significant net loss and accrued expenses related to an SEC investigation, necessitating prudent financial management.
Strategic strengths in the U.S. market entry, global commercialization efforts, and strong cash position position Nanox Imaging for future growth and market success.
Opportunities lie in upcoming Investor Day, FDA clearance for Nanox.ARC, and expansion in Africa, offering avenues for revenue growth and market leadership.

Nanox Imaging reports Q3 revenue growth and strategic advancements

Nanox Imaging's Q3 2023 performance showed revenue growth and strategic advancements. While facing financial challenges and potential execution hurdles, the company's focus on expansion and partnerships positions it for future growth.

Nanox Imaging reports Q4 loss, eyes global expansion and AI

Nanox Imaging's Q4 2023 performance showed a mix of revenue growth and strategic investments in technology and market expansion.
The company's strengths lie in its progress with regulatory clearances, commercialization efforts, and success in AI applications.
Challenges include slow AI adoption, implementation hurdles, and the need to overcome barriers to data sharing and transparency.
Opportunities exist in expanding HealthCCS usage, global market presence, and addressing AI adoption challenges for revenue growth.

Nanox Imaging reports Q1 loss, eyes global expansion and AI growth

Nanox Imaging's Q1 2024 performance reflects revenue generation from AI solutions and system sales amid challenges in gross profit margins and a notable net loss.
The company's strategic strengths in partnerships, product launches, and global expansions position it well for future growth and market competitiveness.
While facing challenges in cost management and profitability, Nanox Imaging holds opportunities in expanded indications, market expansions, and AI solutions deployment.

Nano-X Imaging reports Q2 losses, eyes growth through FDA clearances

Nano-X Imaging (NNOX) showcased progress in commercial and clinical fronts but faces challenges in narrowing losses and optimizing operations.
Strategic collaborations, FDA clearances, and global deployment offer opportunities for growth and market expansion.
The focus on transformative imaging solutions and commercial infrastructure acceleration underlines NNOX's commitment to innovation and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nano-X Imaging Ltd. is engaged in the development of medical imaging systems. Its product Nanox System consists of hardware Nanox.ARC and software Nanox.CLOUD that provides image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic assistive artificial intelligence systems, billing, and reporting. The firm operates through the following segments: Nanox.Arc, AI Solutions, and Radiology Services. The company was founded by Ran Poliakine and Hitoshi Masuya in 2011 and is headquartered in Petach Tikva, Israel.

Riot Blockchain

They may not be the most obvious picks, but they could be quite rewarding down the line.

3 Unusual Growth Stocks to Buy Now

The FDA recently cleared its digital X-ray concept; here's what has to happen next to generate shareholder value.

3 Things Nano-X Needs to Do to Make You Rich

NEVE ILAN, Israel, April 06, 2021 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (www.nanox.vision) (“Nanox” or the “Company”), the innovative medical imaging technology company democratizing healthcare, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020 with the U.S. Securities and Exchange Commission (“SEC”) on April 6, 2021. The annual report on Form 20-F, which contains the Company's audited consolidated financial statements, can be accessed on the SEC's website at www.sec.gov and on the Company's website at www.nanox.vision under “Financials” in the Investors section.

NANO-X IMAGING LTD Files 2020 Annual Report on Form 20-F

The Israeli medical equipment company came out with good news on Friday regarding its single-source digital X-ray imaging system, and the market reacted positively.

Why Is Nano-X Imaging Stock Soaring?

Canopy Growth

Etsy

Marathon Digital Holdings

Nano-X Imaging, Etsy, Mara Digital Holdings and Canopy Growth were our top stock trades for Tuesday. That said, let's look at the charts.

4 Top Stock Trades for Tuesday: NNOX, ETSY, MARA, CGC

JetBlue Airways

Most Nasdaq stocks were sharply higher Monday.

Nano-X Sends Nasdaq Soaring; JetBlue Nears Multi-Year Highs

The company will start shipping its X-ray machines to hospitals in the fourth quarter of 2021.

Nano-X Imaging Receives FDA Clearance for X-Ray Device

The company won FDA clearance for its single-source digital X-ray technology.

Why Nanox Stock Is Skyrocketing Today

NNOX stock is soaring on Monday after Nano-X announced it had reached another regulatory milestone with the FDA. The post NNOX Stock: Nano-X Rockets Higher on Big FDA Milestone appeared first on InvestorPlace.

NNOX Stock: Nano-X Rockets Higher on Big FDA Milestone

Chembio Diagnostics

Chembio Diagnostics Inc (NASDAQ: CEMI) shares are trading higher by 41% in Monday's pre-market session after the company announced the commercial launch of a test to differentiate between COVID-19 and the Flu. Chembio develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases.

Why NNOX Stock And CEMI Stock Are Skyrocketing Today

The stock price of Nano-X Imaging Ltd (NASDAQ: NNOX) increased by over 50% pre-market. This is why it happened.

Nano-X Imaging Stock Price Increased Over 50% Pre-Market: Why It Happened

Nano-X Imaging Ltd (NASDAQ: NNOX) stock is seeing high social media interest on Monday. The company's shares last closed 0.29% lower at $41.33 on Thursday.

What's Happening With Nano-X Imaging Stock?

Tesla

With the NASDAQ and growth sectors rebounding nicely last week, let's take a look at three stocks with some major catalysts heading into April, the first month of the second quarter.

3 Stocks for Early April

NEVE ILAN, Israel, April 02, 2021 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announced today that its single-source Nanox.ARC digital x-ray technology has received 510(k) clearance from the US Food and Drug Administration (the “FDA”).

Nanox Announces FDA Clearance of 510(k) for Single Source Nanox.ARC Digital X-Ray

Investors need to pay close attention to Nano-X Imaging (NNOX) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Nano-X Imaging (NNOX) Stock?

Fluidigm

Guardant Health Inc

Innovation is risky, and these companies are all in.

3 Extraordinary Diagnostics Stocks for 2021

Apple

Boeing

Visa

Boeing, Apple, Nano-X Imaging and Visa were our top stock trades for Monday. Let's have a look at the charts for next week.

4 Top Stock Trades for Monday: BA, AAPL, NNOX, V

NEVE ILAN, Israel, March 15, 2021 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announces that Nanox's Founder and Chief Executive Officer Ran Poliakine will deliver a company presentation and the leadership team will host investor 1x1 meetings during the Oppenheimer 31st Annual Virtual Healthcare Conference, which is being held from March 16 through March 18.

Nanox to Participate in the Virtual 31st Annual Oppenheimer Healthcare Conference

This healthcare disrupter is about to receive FDA clearance to start distributing its new X-ray device.

Is Nano-X a Buy?

On one hand, NNOX stock is supported by a groundbreaking medical innovations. But on the other, economic problems present severe headwinds.

Nano-X Imaging Has the Right Science at the Wrong Time

The X-ray disrupter is almost 50% off its highs.

Nano-X Imaging: Buy the Dip?

Nano-X Imaging's (NNOX) CEO Rand Poliakine on Q4 2020 Results - Earnings Call Transcript

Jumia

Boeing, TJX Companies, Jumia and Nano-X Imaging were our top stock trades from Wednesday. That said, let's look at the charts now.

4 Top Stock Trades for Thursday: BA, TJX, JMIA, NNOX

Management to host conference call and webcast at 8:30 AM ET Management to host conference call and webcast at 8:30 AM ET

Nanox to Announce Fourth Quarter and Full Year 2020 Financial and Operating Results on Tuesday, March 2, 2021

NEVE ILAN, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced that it has priced the previously announced underwritten public offering of 3,091,635 of its ordinary shares by certain non-officer, non-director shareholders (the “selling shareholders”) at a public offering price of $62.50 per share. The offering is expected to close on or about February 16, 2021, subject to satisfaction of customary closing conditions.

News for Nano-X Imaging Stock (NNOX)